现在门已经打开了:对于神经干预主义者来说,关于缺血性中风药物治疗的最新情况
Justin F Fraser1,2,3, Shivani Pahwa4,3, Michael Maniskas5
1Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA Jfr235@uky.edu.
Journal of neurointerventional surgery
|May 31, 2023
概括
最近中风管理方面的进展主要集中在输血疗法,如静脉输血栓溶解和机械血栓切除术. 正在研究新的神经保护疗法,以提高这些干预后的大脑组织存活率.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 血管医学 血管医学
背景情况:
- 在过去的十年中,大血管缺血性中风的管理已经显著发展.
- 再 perfusion 疗法,包括静脉输血栓溶解和机械血栓切除,越来越多地使用.
- 这些疗法旨在恢复血液流向缺血性脑组织.
研究的目的:
- 探索新的治疗方法,以改善大脑组织在再注射后的生存.
- 研究将再输注策略与神经保护疗法结合在一起的潜力.
- 为了利用翻译研究和临床试验对先进的中风治疗的见解.
主要方法:
- 翻译研究模型和临床前范式的审查.
- 分析关于缺血性中风机制的详细研究.
- 检查最近临床试验数据的综合反和神经保护.
主要成果:
- 新出现的证据支持将反疗法与神经保护剂结合起来.
- 证明有效的神经保护药物可以在再注射期间或在再注射后立即使用.
- 临床前和临床研究为这种综合方法提供了基础.
结论:
- 当前的时代强调对缺血性中风的再注射策略.
- 技术进步和临床试验经验使得多方治疗方法成为可能.
- 将再注射与神经保护相结合,代表了急性中风治疗的前沿.
相关概念视频
Venous Thrombosis III: Interprofessional Care
12
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
12
Peripheral Artery Disease III: Interprofessional Care
14
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
14
Acute Coronary Syndrome IV: Interprofessional Care
15
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
15
Atherosclerosis III: Management
16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Coronary Artery Disease V: Interprofessional Care
12
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
12
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


